RECRUITING

Effect of Glucagon on Fasting Insulin Secretion and Glucose Metabolism in Subjects Without Type 2 Diabetes

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Fasting hyperglycemia contributes disproportionately to nonenzymatic glycosylation and the microvascular complications of type 2 diabetes. However, little is known about the regulation of glucose concentrations in the fasting state relative to what is known about the postprandial state. The proposed experiment is part of a series of experiments designed to establish how glucagon and insulin interact with their receptors to control fasting glucose in health and in prediabetes.

Official Title

Effect of Glucagon on Fasting Insulin Secretion and Glucose Metabolism in Subjects Without Type 2 Diabetes

Quick Facts

Study Start:2024-10-01
Study Completion:2027-07-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06424106

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:25 Years to 65 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Individuals with normal or impaired fasting glucose and normal or impaired glucose tolerance
  1. * HbA1c less than 6.5%
  2. * Use of any glucose-lowering agents including metformin or sulfonylureas.
  3. * For female subjects: positive pregnancy test at the time of enrollment or study
  4. * History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.
  5. * Active systemic illness or malignancy.
  6. * Symptomatic macrovascular or microvascular disease.

Contacts and Locations

Study Contact

Kim Osmundson, CCRP
CONTACT
507-255-0907
Osmundson.Kimberly@mayo.edu
Jeanette Laugen
CONTACT
507-255-8110
Laugen.Jeanette@mayo.edu

Principal Investigator

Adrian Vella, MD
PRINCIPAL_INVESTIGATOR
Mayo Clinic

Study Locations (Sites)

Mayo Clinic in Rochester
Rochester, Minnesota, 55905
United States

Collaborators and Investigators

Sponsor: Mayo Clinic

  • Adrian Vella, MD, PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-10-01
Study Completion Date2027-07-01

Study Record Updates

Study Start Date2024-10-01
Study Completion Date2027-07-01

Terms related to this study

Keywords Provided by Researchers

  • Insulin secretion
  • glucagon secretion
  • endogenous glucose production
  • glucose disappearance

Additional Relevant MeSH Terms

  • PreDiabetes